U.S. markets open in 7 hours 10 minutes

VistaGen Therapeutics, Inc. (VTGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1600-0.0300 (-1.37%)
At close: 4:00PM EDT

VistaGen Therapeutics, Inc.

343 Allerton Avenue
South San Francisco, CA 94080
United States
650 577 3600
http://www.vistagen.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Shawn K. SinghCEO & Director498kN/A1963
Dr. H. Ralph SnodgrassFounder, Pres, Chief Scientific Officer & Director416.85kN/A1950
Mr. Jerrold D. Dotson CPACFO, VP & Sec.367.5kN/A1953
Mr. Mark Adrian McPartlandVP of Corp. Devel.300kN/A1966
Dr. Mark A. SmithChief Medical Officer416.85kN/A1955
Dr. Mark J. GinskiSr. VP and Head of Chemistry, Manufacturing & ControlsN/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

VistaGen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.